ASTELLAS PHARMA (Germany) Performance

YPHA Stock  EUR 8.70  0.10  1.16%   
The firm shows a Beta (market volatility) of 0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ASTELLAS PHARMA's returns are expected to increase less than the market. However, during the bear market, the loss of holding ASTELLAS PHARMA is expected to be smaller as well. ASTELLAS PHARMA UNSPADR has an expected return of -0.26%. Please make sure to confirm ASTELLAS PHARMA UNSPADR coefficient of variation, variance, and the relationship between the mean deviation and standard deviation , to decide if ASTELLAS PHARMA UNSPADR performance from the past will be repeated at future time.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ASTELLAS PHARMA UNSPADR has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's technical indicators remain nearly stable which may send shares a bit higher in June 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Price Earnings Ratio22.9825
Dividend Yield0.0297
Payout Ratio0.6818
  

ASTELLAS PHARMA Relative Risk vs. Return Landscape

If you would invest  1,030  in ASTELLAS PHARMA UNSPADR on February 2, 2024 and sell it today you would lose (160.00) from holding ASTELLAS PHARMA UNSPADR or give up 15.53% of portfolio value over 90 days. ASTELLAS PHARMA UNSPADR is producing return of less than zero assuming 1.274% volatility of returns over the 90 days investment horizon. Simply put, 11% of all stocks have less volatile historical return distribution than ASTELLAS PHARMA, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days trading horizon ASTELLAS PHARMA is expected to under-perform the market. In addition to that, the company is 2.03 times more volatile than its market benchmark. It trades about -0.21 of its total potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.07 per unit of volatility.

ASTELLAS PHARMA Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for ASTELLAS PHARMA's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ASTELLAS PHARMA UNSPADR, and traders can use it to determine the average amount a ASTELLAS PHARMA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2071

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsYPHA

Estimated Market Risk

 1.27
  actual daily
11
89% of assets are more volatile

Expected Return

 -0.26
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.21
  actual daily
0
Most of other assets perform better
Based on monthly moving average ASTELLAS PHARMA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ASTELLAS PHARMA by adding ASTELLAS PHARMA to a well-diversified portfolio.

ASTELLAS PHARMA Fundamentals Growth

ASTELLAS Stock prices reflect investors' perceptions of the future prospects and financial health of ASTELLAS PHARMA, and ASTELLAS PHARMA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ASTELLAS Stock performance.

About ASTELLAS PHARMA Performance

To evaluate ASTELLAS PHARMA UNSPADR Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when ASTELLAS PHARMA generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare ASTELLAS Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand ASTELLAS PHARMA UNSPADR market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents ASTELLAS's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.

Things to note about ASTELLAS PHARMA UNSPADR performance evaluation

Checking the ongoing alerts about ASTELLAS PHARMA for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ASTELLAS PHARMA UNSPADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
ASTELLAS PHARMA generated a negative expected return over the last 90 days
Evaluating ASTELLAS PHARMA's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate ASTELLAS PHARMA's stock performance include:
  • Analyzing ASTELLAS PHARMA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ASTELLAS PHARMA's stock is overvalued or undervalued compared to its peers.
  • Examining ASTELLAS PHARMA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating ASTELLAS PHARMA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ASTELLAS PHARMA's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of ASTELLAS PHARMA's stock. These opinions can provide insight into ASTELLAS PHARMA's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating ASTELLAS PHARMA's stock performance is not an exact science, and many factors can impact ASTELLAS PHARMA's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ASTELLAS PHARMA UNSPADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the ASTELLAS PHARMA UNSPADR information on this page should be used as a complementary analysis to other ASTELLAS PHARMA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for ASTELLAS Stock analysis

When running ASTELLAS PHARMA's price analysis, check to measure ASTELLAS PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ASTELLAS PHARMA is operating at the current time. Most of ASTELLAS PHARMA's value examination focuses on studying past and present price action to predict the probability of ASTELLAS PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ASTELLAS PHARMA's price. Additionally, you may evaluate how the addition of ASTELLAS PHARMA to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Please note, there is a significant difference between ASTELLAS PHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine if ASTELLAS PHARMA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ASTELLAS PHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.